Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CEA-B039 | Human | Human Soluble CD38 ELISA Kit | |||
| CD8-H8214 | Human | Biotinylated Human CD38 Protein, Avitag™ |  |
|
|
| HGS-S316 | Rabbit | Recombinant Monoclonal Anti-CD38 Antibody, Rabbit (6A5) | |||
| CD8-H82F5 | Human | Biotinylated Human CD38 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| CD8-HF255 | Human | FITC-Labeled Human CD38 Protein, Fc Tag |  |
|
|
| CD8-HF2H5 | Human | FITC-Labeled Human CD38 Protein, His Tag (MALS verified) |  |
|
|
| MBC-K010 | Human | Human CD38-coupled Magnetic Beads | |||
| CD8-M5223 | Mouse | Mouse CD38 Protein, His Tag |  |
|
|
| CD8-C5223 | Cynomolgus | Cynomolgus CD38 Protein, His Tag |  |
|
|
| CD8-H5253 | Human | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD8-H5255 | Human | Human CD38 Protein, Fc Tag (MALS verified) |  |
|
|
| CD8-H82E7 | Human | Biotinylated Human CD38 Protein, Avitag™,His Tag |  |
|
|
| CD8-H5224 | Human | Human CD38 Protein, His Tag (MALS verified) |  |
|
|
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Approved | Janssen Global Services Llc | Darzalex Faspro, Darzquro | Japan | Amyloidosis | Janssen Pharmaceutical Kk | 2020-05-01 | Multiple Myeloma; Rejection of organ transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Rejection in heart transplantation | Details | |
| Isatuximab | SAR-650984 | Approved | Immunogen Inc | Sarclisa | Japan | Multiple Myeloma | Sanofi | 2020-03-02 | Gastrointestinal Hemorrhage; Leukemia, Myeloid, Acute; Macroglossia; Lymphoma; Nausea; Hepatomegaly; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Satiety Response; Diarrhea; Hematologic Neoplasms; Multiple Myeloma; Neoplasms; Purpura; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Lymphadenopathy; Paraproteinemias; Constipation; Goiter, Nodular | Details |
| Daratumumab | JNJ-54767414 | Approved | Janssen Global Services Llc | Darzalex, 兆珂, 兆珂速 | Mainland China | Multiple Myeloma | Janssen-Cilag International Nv | 2015-11-16 | Urinary Bladder Neoplasms; Hypersensitivity; POEMS Syndrome; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Urologic Neoplasms; Alzheimer Disease; Amyloidosis; Lymphoma, Extranodal NK-T-Cell; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Rejection of renal transplantation; Rejection of organ transplantation; Multiple Myeloma; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Hodgkin Disease; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Genital Neoplasms, Male; Paraproteinemias; Kidney Neoplasms; Purpura, Thrombocytopenic, Idiopathic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| CART-38 | CART-38 | The First Affiliated Hospital Of Soochow University | Details | ||
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms | Details |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| CID-103 | CID-103; TSK011010 | Phase 1 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma | Details |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | Details | ||
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| CART-38（University of Pennsylvania） | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| CM-313(Connaught Biomedical Technology) | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
| KP-1237 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc | Multiple Myeloma | Details | |
| Mezagitamab | TAK-079 | Phase 2 Clinical | Takeda | Hematologic Neoplasms; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic; Glomerulonephritis, IGA; Nephrosis; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| TAK-169 | TAK-169 | Phase 1 Clinical | Molecular Templates Inc | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
| GEN-3014 | GEN-3014 | Phase 2 Clinical | Genmab A/S | Multiple Myeloma | Details |
| Felzartamab | TJ-202; MOR-202; MOR-03087 | Phase 3 Clinical | Morphosys Ag | Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Multiple Myeloma; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
This web search service is supported by Google Inc.
A-Z
